<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02507492</url>
  </required_header>
  <id_info>
    <org_study_id>RM-493-011</org_study_id>
    <secondary_id>2014-002392-28</secondary_id>
    <nct_id>NCT02507492</nct_id>
  </id_info>
  <brief_title>RM-493 Treatment Trial in Proopiomelanocortin (POMC) Deficient Patients</brief_title>
  <official_title>RM-493 Treatment Trial in Proopiomelanocortin (POMC) Deficient Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of a once daily subcutaneous (SC)&#xD;
      injection of RM-493, in subjects with POMC (propiomelanocortin) or other related rare genetic&#xD;
      mutations, on body weight, metabolic function and blood pressure. Patients who respond during&#xD;
      the initial 84 days of treatment can enter into long-term (2-year) extensions. The study drug&#xD;
      (RM-493) will be administered in an unblinded fashion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of RM-493 on Body weight</measure>
    <time_frame>Day 1 through Day 84</time_frame>
    <description>Change of body weight after Treatment with RM-493.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of RM-493 on metabolic serum parameters</measure>
    <time_frame>Day 1 through Day 84</time_frame>
    <description>Measurement of the effect of RM-493 on metabolic serum parameters as measured by blood test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of RM-493 on blood pressure</measure>
    <time_frame>Day 1 through Day 84</time_frame>
    <description>Measurement of the effect of RM-493 on blood pressure by daily blood pressure measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of RM-493 on hunger</measure>
    <time_frame>Day 1 through Day 84</time_frame>
    <description>Measurement of the effect of RM-493 on hunger as measured by the Global Hunger Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of RM-493 on body composition/Energy expenditure</measure>
    <time_frame>Day 1 through Day 84</time_frame>
    <description>Measurement of the effect of RM-493 on body composition/Energy expenditure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of RM-493 on weight loss after treatment continuation of 2 years</measure>
    <time_frame>Day 1 through Day 730</time_frame>
    <description>Measurement of the effect of RM-493 on weight loss after treatment continuation of 2 years</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Homozygous or Compound Heterozygous POMC, LEPR or PCSK1 Gene Mutation</condition>
  <arm_group>
    <arm_group_label>RM-493 Once Daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose once daily in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RM-493</intervention_name>
    <arm_group_label>RM-493 Once Daily</arm_group_label>
    <other_name>setmelanotide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Homozygous or compound heterozygous (different gene mutation on both alleles) POMC,&#xD;
             LEPR or PCSK1 gene mutation&#xD;
&#xD;
          -  Obesity (BMI &gt; 30 kg/m2; + 2 BMI SDS)&#xD;
&#xD;
          -  No other therapeutic option, which might cure the patient (e.g. bariatric surgery (see&#xD;
             chapter 8))&#xD;
&#xD;
          -  Negative Pregnancy test&#xD;
&#xD;
          -  Highly effective contraception in women (defined as pearl index &lt; 1), if necessary&#xD;
             also for partners of test persons)&#xD;
&#xD;
          -  No participation in other clinical trials according to AMG (Arzneimittelgesetz) (2&#xD;
             months before and after) at the time of this trial&#xD;
&#xD;
          -  Normal or minimally elevated blood pressure (measured in 24RR monitoring or similar&#xD;
             methods) according the guidelines of the ESH (European Society of Hypertension) and&#xD;
             Deutsche Hochdruckliga: systolic &gt; 159 mmHg/diastolic 99 mmHg&#xD;
&#xD;
          -  sufficient kidney and liver function (Creatinine, ALT, AST)&#xD;
&#xD;
               -  normal values Alanine-Aminotransferase (ALT) (female): &lt; 31 U/l&#xD;
&#xD;
               -  normal values Alanine-Aminotransferase (ALT) (male): &lt; 41 U/l&#xD;
&#xD;
               -  normal values Aspartate-Aminotransferase (AST) (female &gt; 17 years): &lt; 35 U/l;&#xD;
                  (female &lt; 17 years): 16- 46 U/l&#xD;
&#xD;
               -  normal values Aspartate-Aminotransferase (AST) (male &gt; 17 years): &lt; 50 U/l; (male&#xD;
                  &lt; 17 years): 16-46 U/l&#xD;
&#xD;
               -  normal values bilirubins (male and female) up to 1,2 mg/dl&#xD;
&#xD;
               -  normal values Creatinine (female &gt; 15 years): 0,51-0,95 mg/dl) ; (female &lt; 15&#xD;
                  years): 0,46-0,77 mg/dl&#xD;
&#xD;
               -  normal values Creatinine (male &gt; 15 years): 0,67 - 1,17 mg/dl) ; (male &lt; 15&#xD;
                  years): 0,46-0,77 mg/dl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or Breastfeeding&#xD;
&#xD;
          -  All contraindications against study medication (including auxiliary substances)&#xD;
&#xD;
          -  Interactions with study medication&#xD;
&#xD;
          -  Participation of the patient in a clinical study within the last 2 months&#xD;
&#xD;
          -  Intolerance against albumin&#xD;
&#xD;
          -  Concomitant diseases, impaired organ functions, except for known, concurrent GI&#xD;
             disorders or other clinical findings expected in PCSK1 or LEPR gene disorders&#xD;
&#xD;
          -  Renal insufficiency (Creatinine &gt; 0,95 mg/dl (female), &gt; 1,17 mg/dl (male))&#xD;
&#xD;
          -  Impaired liver function (Bilirubins &gt; 1.2 mg/dl)&#xD;
&#xD;
          -  Neurological / psychiatric diseases&#xD;
&#xD;
          -  HIV Infection&#xD;
&#xD;
          -  Active Hepatitis B or C&#xD;
&#xD;
          -  Melanoma or Melanoma occurrence in the family history&#xD;
&#xD;
          -  Non-compliance&#xD;
&#xD;
          -  Subjects who are legally detained in an official institution&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Susanna Wiegand, PD Dr.</last_name>
    <phone>+49 30 450 566887</phone>
    <email>susanna.wiegand@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Kühnen, Dr.</last_name>
    <phone>+49 30 450 450 666839</phone>
    <email>peter.kuehnen@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanna Wiegand, PD Dr.</last_name>
      <phone>+49 30 450 566887</phone>
      <email>susanna.wiegand@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Peter Kühnen, Dr.</last_name>
      <phone>+49 30 450 450 666839</phone>
      <email>peter.kuehnen@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Heiko Krude, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Kühnen, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>May 29, 2015</study_first_submitted>
  <study_first_submitted_qc>July 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2015</study_first_posted>
  <last_update_submitted>February 19, 2016</last_update_submitted>
  <last_update_submitted_qc>February 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>PD Dr. Susanna Wiegand</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>POMC, LEPR, PCSK1</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

